ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2024
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Revolutionizing cancer diagnosis and dose biodistribution: a meta-analysis of [68ga] FAPI- 46 vs. [18f] FDG imaging.Systematic reviews · 2025Pooled it
- Clinical Evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- FAP-targeted [European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Clinical value of multi-time-pointEndocrine · 2026Article
- Comparative evaluation of [European journal of nuclear medicine and molecular imaging · 2026Article
- First-in-human study of a novel bifunctional PET tracer [European journal of nuclear medicine and molecular imaging · 2026Article
- The Current Status of Radionuclide Tumor Targeting Diagnosis and Therapy Based on FAP-2286: From Preclinical Studies to Clinical Application.Molecular diagnosis & therapy · 2026Review
- Engineering a modular FAP-targeting ferritin-based drug nanocarrier for enhanced glioblastoma theranostics.Theranostics · 2026Article
- Fibroblast activation Protein-Targeted PET/CT using [18 F]FAP-2286 for the evaluation of lung cancer: A comparative study with [18 F]FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- Meeting Upcoming Clinical and Diagnostic Needs in Oncologic Imaging: A Structured Reporting System for Fibroblast-Activation-Protein-Targeted Imaging-FAP-RADS Version 1.0.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- CD70: An emerging target for integrated cancer diagnosis and therapy.Clinical and translational medicine · 2025Review
- Preclinical evaluation of [Scientific reports · 2025Article
- SNMMI Procedure Standard/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Specific reaction conditions for efficient automatedFrontiers in medicine · 2025Article
- Multivalent FAPI-based radiopharmaceuticals in PET/CT: from cancer diagnostics to theranostics.American journal of nuclear medicine and molecular imaging · 2025Article
- Review
- Comparison ofFrontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Fibroblast activation protein (FAP), expressed in the tumor microenvironment of a variety of cancers, has become a target of novel PET tracers. The purpose of this report is to evaluate the imaging characteristics of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.